🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Have a new project to share,,,Dr. John Sfakianos and I will be starting a new podcast, #Men’s #Health #On #Tap in partnership with Tilray Brands. We will cover all areas affecting Men’s Health and why men have to engage in their health journey! Stay tuned in #Movember

Super excited to launch this with Dr. Steven Kaplan!

Very excited to join Dr. Steven Kaplan on this awesome podcast trying to educate and encourage Men to talk about their health. Tilray Brands #MensHealth on Tap.

Pre- and postradical cystectomy tumor-informed ctDNA dynamics is a powerful predictor of oncological outcomes: those who convert from detectable to undetectable ctDNA fare worse than those staying undetectable Reuben Ben-David ד''ר ראובן בן דוד Reza Mehrazin, MD Dr. John Sfakianos doi.org/10.1111/bju.16…

Fantastic job Reuben Ben-David ד''ר ראובן בן דוד ! The more we study ctDNA the more exciting it becomes. Still a lot of work ahead of us to understand its best case use! Mount Sinai Department of Urology The Tisch Cancer Institute

Delighted to share our new paper on rob PC-RPLND 🏥11 centers > 173 pts 🤖4% conversion rate: higher after salvage chemo and mass>5cm 🩸EBL 100, LOS 2d ➡️median FU 22mo: 8 recur (3 in-field) ↗️4yr RFS 93% Dr. Hooman Djaladat Eur Urol Focus USC Urology 🔗authors.elsevier.com/c/1k6ci8Yy0LUa…

📝 New Study Highlights: Comparing BCG and Gemcitabine/Docetaxel (Gem/Doce) for Intermediate-Risk #NMIBC As BCG shortages persist, alternative therapies for IR-NMIBC are crucial. Recent data reveals BCG's superiority over Gem/Doce in high-grade RFS and any-grade RFS. Maintenance

So blessed to have been Promoted to Professor and obtain a fundable score for our second R01. All this is only because I have been lucky enough to train with, collaborate with and just allowed to be around so many amazing individuals! Thank you to all of you! Mount Sinai Department of Urology

Couldn’t have done it without you! Thanks for being a ln amazing partner through all this!

Congrats and Great work Reuben! This is the beginning of what could be practice changing for #bladdercancer patients. Lots more work to do! Mount Sinai Department of Urology The Tisch Cancer Institute Natera

In Episode 3 of "Men's Health on Tap," Dr. John Sfakianos and Dr. Steven Kaplan chat with personal trainer & two-time Golden Gloves Champion, Ngo Okafor. They discuss the importance of regular exercise for overall health. Listen to the full episode ow.ly/kPCX50UYP8U $TLRY

Our third #Men's Health on Tap is avaiable for viewing. Dr. John Sfakianos and I interview Ngo Okafor and discuss his incredible journey and how exercise, balance and persistence are keys to a joyful life. see him on the TODAY. thx to Tilray Brands. open.spotify.com/episode/5TJb4m…

Beyond the abstract on UroToday.com —now with an extra figure on ctDNA conversion dynamics! Our pre- and post-cystectomy ctDNA analysis offers insights into how radical cystectomy clears ctDNA in a subset of patients. Conversely, those with persistently detectable ctDNA that do not

So many congrats, John Dr. John Sfakianos and colleagues on the well-deserved recognition!!

Had an amazing trip University of British Columbia visiting Martin Gleave Peter Black and team. Amazing program with exceptional science. Thoughtful conversations with all the scientist and residence. More importantly the food and wine were fantastic 😀. Thank you and looking forward to collaborating.

Thank you Horowitz Lab @Icahn School of Medicine Mount Sinai as you and others know success is only as strong as its team! Thank you for all the knowledge and support throughout the years.

Please listen to our 4th podcast of Men's Health on Tap sponsored by Tilray Brands. Dr. John Sfakianos and I interview Shari Melamed-Kaplan , a global leader in cardiac health care and responsible for helping launch Lipitor and Norvasc in the US...lots to learn! open.spotify.com/episode/0daHj8…

De-Escalating treatment based on serial #Biomarker #ctDNA assessment should be the goal in #MIBC #BladderCancer Dr. John Sfakianos 👉This could not only mean #BladderSparing but also removing neoadjuvant treatment and do #RadicalCystectomy w/o systemic treatment #EAU2025 @uroweb

Thank you #EAU2025 and the organizers of this plenary for allowing me to present the exciting data on the use of #ctDNA signatera for improving risk stratification for #bladdercancer . Natera Mount Sinai Department of Urology The Tisch Cancer Institute

Discussant Dr. John Sfakianos pointing out knowledge gaps: ❓is ctDNA predictive ❓can we de-escalate for ctDNA(-) ❓can we improve for ctDNA(+) #MODERN will help answer some of these although w/o neoadjuvant IO